Trial Profile
A study to evaluate utilization and outcomes of Eribulin in patients with triple negative metastatic breast cancer
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 21 Feb 2017
Price :
$35
*
At a glance
- Drugs Eribulin (Primary)
- Indications Breast cancer
- Focus Adverse reactions; Therapeutic Use
- 21 Feb 2017 New trial record